Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: Evidence for gene-environment interaction in healthy volunteers

Journal of Hypertension

Volumn 28, Issue 12, 2010, Pages 2414-2421

  Lely, A Titia ^a   Heerspink, Hiddo J Lambers ^b   Zuurman, Mike ^a   Visser, Folkert W ^a   Kocks, Menno J A ^a   Boomsma, Frans ^c   Navis, Gerjan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin II infusion; Angiotensin converting enzyme genotype; Angiotensinconverting enzyme inhibition; Blood pressure; Sodium intake

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; SODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PRIMER DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ENZYME INHIBITION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; ADOLESCENT; BLOOD PRESSURE; GENETICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; REFERENCE VALUE;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BASE SEQUENCE; BLOOD PRESSURE; DNA PRIMERS; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; PLACEBOS; POLYMERASE CHAIN REACTION; REFERENCE VALUES; SODIUM, DIETARY;

EID: 79956334637     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833eaf34     Document Type: Article

References (42)

1. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346. (Pubitemid 20370444)
2. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliott HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148-2153. (Pubitemid 28527474)
3. Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study. Pharmacogenet Genomics 2010; 20:77-85.
4. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM. Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - A systematic review. Curr Control Trials Cardiovasc Med 2005; 6:16.
5. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685. (Pubitemid 28306794)
6. Heeg JE, de Jong PE, van der Hem GK, De ZD. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-279. (Pubitemid 19202486)
7. Navis G, de Jong P, Donker AJ, van der Hem GK, de Zeeuw D. Diuretic effects of angiotensin-converting enzyme inhibition: Comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987; 9:743-748. (Pubitemid 17095578)
8. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002; 13:1025-1033. (Pubitemid 34274099)
9. Van Der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, et al. Angiotensin converting enzyme insertion/deletion polymorphism and shortterm renal response to ACE inhibition: Role of sodium status.. Kidney Int Suppl 1997; 63:S23-S26. (Pubitemid 28020426)
10. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 2000; 57:274-281. (Pubitemid 30227775)
11. Staessen JA, Wang J, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. Hypertension 1997; 15 (12 Pt 2):1579-1592. (Pubitemid 28029652)
12. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7:2550-2558. (Pubitemid 27469561)
13. Bos H, Laverman GD, Henning RH, Tiebosch AT, de Jong PE, de Zeeuw D, Navis G. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. J Renin Angiotensin Aldosterone Syst 2003; 4:106-112. (Pubitemid 36790182)
14. Largo R, Gomez-Garre D, Soto K, Marron B, Blanco J, Gazapo RM. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. J Am Soc Nephrol 1999; 33:732-739. (Pubitemid 29091657)
15. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995; 92:3105-3112.
16. Rogacz S, Williams GH, Hollenberg NK. Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet. Hypertension 1990; 15:376-380. (Pubitemid 20137591)
17. Volpe M, Muller FB, Trimarco B. Transient enhancement of sympathetic nervous system activity by long-term restriction of sodium intake. Circulation 1985; 72:47-52. (Pubitemid 15069576)
18. Admiraal PJ, Danser AH, Jong MS, Pieterman H, Derkx FH, Schalekamp MA. Regional angiotensin II production in essential hypertension and renal artery stenosis. Hypertension 1985; 21:173-184.
19. Derkx FH, Tan-Tjiong L, Wenting GJ, Boomsma F, Man in 't Veld AJ, Schalekamp MA. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension 1983; 5:244-256. (Pubitemid 13164353)
20. Koiter J, Navis G, de Jong PE, van Gilst WH, De Zeeuw D. Sample dilution: A methodological pitfall in the measurement of tissue but not serum aceactivity. J Pharmacol Toxicol Methods 1998; 39:45-49. (Pubitemid 28224473)
21. Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y, et al. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 2003; 26:301-306. (Pubitemid 36575784)
22. Jacobsen PK, Tarnow L, Parving HH. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 2006; 69:293-1295.
23. Lachurie ML, Azizi M, Guyene TT, henc-Gelas F, Menard J. Angiotensinconverting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995; 91:2933-2942.
24. Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995; 25:1266-1269.
25. Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA, Schunkert H. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998; 16:1879-1883. (Pubitemid 29002363)
26. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99:2375-2385. (Pubitemid 27227714)
27. Boddi M, Poggesi L, Coppo M, Zarone N, Sacchi S, Tania C, et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 1998; 31:836-842. (Pubitemid 28108584)
28. Kocks MJ, Buikema H, Gschwend S, Boomsma F, de Zeeuw D, Navis G. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. J Cardiovasc Pharmacol 2003; 42:601-606. (Pubitemid 37305977)
29. Kocks MJ, Gschwend S, de Zeeuw D, Navis G, Buikema H. Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. J Pharmacol Exp Ther 2004; 310:1183-1189. (Pubitemid 39108940)
30. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH. Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst 2004; 5:130-134. (Pubitemid 39406721)
31. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996; 17:787-794. (Pubitemid 26160788)
32. Conlin PR, Moore TJ, Williams GH, Hollenberg NK. Rapid modulation of renal and adrenal responsiveness to angiotensin II. Hypertension 1993; 22:832-838. (Pubitemid 23358090)
33. Rogacz S, Hollenberg NK, Williams GH. Role of angiotensin II in the hormonal, renal, and electrolyte response to sodium restriction. Hypertension 1987; 9:289-294. (Pubitemid 17035233)
34. Gunther S, Gimbrone MA Jr, Alexander RW. Regulation by angiotensin II of its receptors in resistance blood vessels. Nature 1980; 287:230-232. (Pubitemid 10019771)
35. Makita N, Iwai N, Inagami T, Badr KF. Two distinct pathways in the downregulation of type-1 angiotension II receptor gene in rat glomerular mesangial cells. Biochem Biophys Res Commun 1992; 185:142-146.
36. Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Bohm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension 1998; 31:1272-1277. (Pubitemid 28248827)
37. Brown NJ, Blais C Jr, Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol 1998; 32:373-377. (Pubitemid 28399665)
38. Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2001; 2:14-18. (Pubitemid 33687414)
39. Hollenberg NK, Fisher ND, Price DA, Williams GH. Effect of ACE inhibition on pressor, renal vascular, and adrenal responses to infusion of angiotensin I in normal subjects eating a low-salt diet. Am J Hypertens 2000; 13:498-503. (Pubitemid 30330711)
40. Fisher ND, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999; 56:635-641. (Pubitemid 29353162)
41. Kramer AB, Laverman GD, Van Goor H, Navis G. Inter-individual differences in antiproteinuric response to ACE in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol 2003; 201:160-167. (Pubitemid 37121215)
42. Lufft V, Kliem V, Hamkens A, Bleck JS, Eisenberger U, Petersen R, et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998; 12:409-415. (Pubitemid 28446130)